ArticleJournal of pharmaceutical health care and sciences2026
Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAntiepileptic drugs must be continually used to control seizures in pregnant people with epilepsy. Lacosamide (LCM) and perampanel (PER) are third-generation antiepileptic drugs that were introduced to clinical practice in 2008 and 2012, respectively. LCM and PER are increasingly being prescribed. However, little information is available regarding the safety or placental transfer of LCM and PER during pregnancy. We investigated the placental permeability of LCM in vivo and the effects of LCM and PER on efflux transporters in human placental cells in vitro.
methodsClinical umbilical cord and maternal plasma samples were collected from a woman who had been receiving a regular oral regimen of 100 mg LCM twice daily. The LCM concentrations in the samples were quantified using ultra-high-performance liquid chromatography/tandem mass spectrometry. Accumulation assays were conducted using in vitro syncytiotrophoblast models to determine the effects of LCM and PER on the functions of efflux transporters, including breast cancer resistance protein (BCRP/ABCG2), multidrug resistance proteins (MRPs/ABCCs), and P-glycoprotein (P-gp/ABCB1).
resultsThe LCM concentrations in the maternal plasma and umbilical cord plasma samples were 4.02 µg/mL (predelivery trough level) and 3.22 µg/mL (3.5 h after last dose), respectively. The LCM concentration in the umbilical cord plasma was near the lower end of the maternal therapeutic range, and the fetal-to-maternal plasma concentration ratio likely remained below 1.0. Therapeutic concentrations of LCM and PER did not increase the accumulation of fluorescent substrates of the efflux transporters in the in vitro assays. In contrast, high LCM doses increased the accumulation of BODIPY™ FL prazosin, a BCRP substrate, whereas PER did not affect the accumulation of any substrate.
conclusionsLCM was transferred to the fetus at concentrations close to the lower end of the therapeutic range, suggesting that fetal plasma levels did not exceed the maternal levels. High LCM concentrations inhibited BCRP function in vitro, whereas PER did not inhibit major placental efflux transporters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.